Cat. #162123
Humanised OX40 knockin mouse
Cat. #: 162123
Sub-type: Mouse
Disease: Autoimmune disease;Autoimmunity;Inflammation;Inflammatory disease;Inflammatory diseases
Model: Knock-in
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Mark Cragg
Institute: University of Southampton
Primary Citation: Griffiths J. et al. 2020. J Immunother Cancer. 8(2):e001557. PMID: 33428585
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Tool name: Humanised OX40 knockin mouse
- Cancers detailed: Broadly Applicable
- Research fields: Cancer;Immunology;Immuno-oncology
- Tool sub type: Mouse
- Disease: Autoimmune disease;Autoimmunity;Inflammation;Inflammatory disease;Inflammatory diseases
- Model: Knock-in
- Description: A knock-in mouse that expressing human OX40 extracellular domain with a mouse transmembrane and intracellular tail into the endogenous mouse OX40 locus. The resulting mouse expresses a receptor to which anti-human OX40 antibodies bind but which still engages with the mouse intracellular signalling machinery. Homozygous KI mice are KO for mouse OX40. Heterozygous mice express one human allele and one mouse allele. This mouse model was created to assess the immunotherapeutic potential of a panel of anti-hOX40 mAbs (Griffiths et al. 2020).
- Production details: A hOX40 chimeric construct was used to generate the hOX40 knockin mice. Schematic of the construct can be viewed in the primary publication (Griffiths et al. 2020).
Target Details
- Target: hOX40
- Target background: OX40 is a secondary co-stimulatory immune checkpoint molecule. It is being assessed for therapeutic potential
References
- Griffiths J. et al. 2020. J Immunother Cancer. 8(2):e001557. PMID: 33428585
